Loading viewer...
earnings
Format: PDF earnings
Ambu reported strong Q1 2024/25 results with 19.5% organic revenue growth and 16.1% EBIT margin. The company raised full-year guidance to 11-14% revenue growth and 13-15% EBIT growth, driven by solid performance in pulmonology and urology/ENT/GI segments.
investor_presentation
13 Pages
earnings
27 Pages
Sunoco Logistics Partners
Shanghai Junshi Biosciences H1 2021 Interim Results Presentation
earningsearnings
33 Pages
Shanghai Junshi Biosciences Co., Ltd.